iRhythm

Data published in PLOS One shows continuous monitoring leads to earlier diagnosis and prevents adverse cardiac events, furthering the case for cardiac screening.

The two companies aim to collaborate on solutions providing early warnings, enabling the identification of patients that could otherwise go undiagnosed.

The application also provides reminders and education, answering common questions and offering recommendations on the use of the ZIO Patch.

The new cash will be used to further grow iRhythm's ZIO Service, which has been used with almost 250,000 patients at over 800 institutions across the U.S.